Amedisys Reports First Quarter 2019 Financial Results and Reaffirms 2019 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Amedisys (AMED) PT Raised to $127 at Craig-Hallum
May 1, 2019 3:28 PM EDTCraig-Hallum analyst Kevin Ellich raised the price target on Amedisys (NASDAQ: AMED) to $127.00 while maintaining a Hold rating following results.
Strong start to the yearmargin expansion to slow before picking back up due to CCH acquisition... MoreAmedisys (AMED) Tops Q1 EPS by 21c, Offers FY Guidance
April 30, 2019 4:37 PM EDTAmedisys (NASDAQ: AMED) reported Q1 EPS of $1.11, $0.21 better than the analyst estimate of $0.90. Revenue for the quarter came in at $467.3 million versus the consensus estimate of $460.61 million.
GUIDANCE:
Amedisys sees FY2019 EPS of $3.98-$4.09, versus the consensus of $4.02. Amedisys sees... More
